Literature DB >> 15260847

Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.

Shingo Kamoshida1, Hiroshi Matsuoka, Kazuya Shiogama, Atsuji Matsuyama, Ryoichi Shimomura, Ken-Ichi Inada, Morito Maruta, Yutaka Tsutsumi.   

Abstract

High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers. However, low TS expression does not necessarily imply chemosensitivity. Inactivation of p16(INK4a) correlates with poor prognosis in various cancers. We immunohistochemically evaluated the relationship between the expression of TS, p16(INK4a), CDK4 and cyclin D1 and the effect of 5-FU-based chemotherapy in colorectal cancers. After antigen retrieval, immunoperoxidase staining was performed on the paraffin-embedded, biopsy and surgical specimens of 37 advanced colorectal cancers preoperatively treated with peroral administration of 5-FU derivatives. As a control group, 31 colorectal cancers without preoperative treatment were analyzed. High TS expression was found in 23 (74%) of 31 tumors resected from histological non-responders and in 19 (61%) of 31 controls but in none of six responders. High p16(INK4a) expression was seen in 83% of the responders, 52% of the non-responders and 32% of the controls. The TS-low/p16(INK4a)-high phenotype was noted in 83% of the responders, but only in 3% of the non-responders (P = 0.0001). Induction of p16(INK4a) expression after chemotherapy was predominantly seen in the responders. Neither CDK4 nor cyclin D1 expression was related to the chemotherapeutic effects. In conclusion, the combination of low expression of TS and induction of p16(INK4a) after chemotherapy can be important indicators of the sensitivity to 5-FU-based chemotherapy in colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15260847     DOI: 10.1111/j.1440-1827.2004.01665.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

2.  Prognostic and predictive value of thymidylate synthase expression in colon cancer.

Authors:  Gerasimos Tsourouflis; Stamatios E Theocharis; Anastasia Sampani; Athina Giagini; Alkiviadis Kostakis; Gregory Kouraklis
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

3.  Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.

Authors:  Kawai Yau; Patricia Price; Radhakrishma G Pillai; Eric Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

Review 4.  Tumour suppressor genes in chemotherapeutic drug response.

Authors:  Dulcie Lai; Stacy Visser-Grieve; Xiaolong Yang
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

5.  Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F.

Authors:  B G Le François; J A Maroun; H C Birnboim
Journal:  Br J Cancer       Date:  2007-10-09       Impact factor: 7.640

6.  Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy.

Authors:  Satoshi Nishino; Ayumi Itoh; Hiroshi Matsuoka; Kotaro Maeda; Shingo Kamoshida
Journal:  Mol Clin Oncol       Date:  2013-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.